Integrated Advisors Network LLC increased its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 19.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,125 shares of the biopharmaceutical company’s stock after buying an additional 1,325 shares during the period. Integrated Advisors Network LLC’s holdings in Alexion Pharmaceuticals were worth $930,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. grew its holdings in Alexion Pharmaceuticals by 29.2% during the 3rd quarter. Victory Capital Management Inc. now owns 190,442 shares of the biopharmaceutical company’s stock worth $21,792,000 after acquiring an additional 43,098 shares in the last quarter. Banco Santander S.A. grew its holdings in Alexion Pharmaceuticals by 209.7% during the 3rd quarter. Banco Santander S.A. now owns 7,023 shares of the biopharmaceutical company’s stock worth $804,000 after acquiring an additional 4,755 shares in the last quarter. Glassman Wealth Services grew its holdings in Alexion Pharmaceuticals by 76.0% during the 3rd quarter. Glassman Wealth Services now owns 227 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 98 shares in the last quarter. Sector Gamma AS grew its holdings in Alexion Pharmaceuticals by 24.5% during the 3rd quarter. Sector Gamma AS now owns 215,068 shares of the biopharmaceutical company’s stock worth $24,610,000 after acquiring an additional 42,288 shares in the last quarter. Finally, Kestra Private Wealth Services LLC acquired a new position in Alexion Pharmaceuticals during the 3rd quarter worth approximately $217,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals stock traded down $1.26 during trading hours on Tuesday, reaching $126.55. 7,552 shares of the stock were exchanged, compared to its average volume of 2,196,389. The stock has a market cap of $27.97 billion, a P/E ratio of 29.86, a P/E/G ratio of 0.97 and a beta of 1.31. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.26 and a current ratio of 3.81. Alexion Pharmaceuticals, Inc. has a 52-week low of $72.67 and a 52-week high of $128.57. The firm’s 50 day moving average is $120.72 and its 200 day moving average is $111.33.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $3.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.60 by $0.64. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The business’s revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.79 EPS. Equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 11.14 EPS for the current fiscal year.
ALXN has been the subject of several analyst reports. Piper Sandler boosted their price target on shares of Alexion Pharmaceuticals from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. Svb Leerink lowered their target price on shares of Alexion Pharmaceuticals from $163.00 to $159.00 and set an “outperform” rating for the company in a report on Friday, October 30th. Raymond James lowered their target price on shares of Alexion Pharmaceuticals from $156.00 to $151.00 and set an “outperform” rating for the company in a report on Friday, July 31st. UBS Group assumed coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, October 28th. They issued a “neutral” rating and a $133.00 target price for the company. Finally, SunTrust Banks upped their target price on shares of Alexion Pharmaceuticals from $135.00 to $155.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $143.60.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Further Reading: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.